Department of Endocrinology, Ege University Hospital, 35100 Izmir, Turkey.
J Diabetes Complications. 2009 Nov-Dec;23(6):401-8. doi: 10.1016/j.jdiacomp.2008.09.005. Epub 2008 Oct 31.
The 1alpha,25-dihydroxyvitamin D(3) [1alpha,25(OH)(2)D(3)] plays an essential role in mineral balance but has also been recognized as a powerful modulator of immune response. We aimed to examine the effect of the 1alpha,25(OH)(2)D(3) treatment on insulin/c-peptide, catalase, superoxide dismutase (SOD), and blood glucose in rats that take streptozotocin (STZ).
Forty pieces of male rats of Albino family whose average weights were 261.00+/-07.62 g were used in the study. Rats were made diabetic by giving STZ of 40 mg/kg during 5 days through intraperitoneal path. Some of the diabetic group and nondiabetic group were received 1alpha,25(OH)(2)D(3). The levels of SOD, insulin, c-peptide, glucose, SOD, and catalase were measured at the zero, second, fourth, and sixth weeks.
Erythrocyte SOD levels didn't show a significant difference at the end of the sixth week in all groups when compared to the beginning. While erythrocyte catalase levels didn't show a significant difference in nondiabetic control and nondiabetic with vitamin D, and diabetic with vitamin D groups at the end of sixth week when compared to the beginning, a significant measurement was made in diabetic without vitamin D group. Maximal insulinitis scoring values were observed in diabetic without vitamin D that didn't receive 1alpha,25(OH)(2)D(3) treatment.
The highness of insulin and c-peptide levels in the group that received treatment when compared to other groups and the lowness of oxidative markers such as SOD, catalase in this study can be explained by the fact that 1alpha,25(OH)(2)D(3) treatment prevents the intervention of apoptosis mechanism.
1α,25-二羟维生素 D(3)[1α,25(OH)2D(3)]在矿物质平衡中起着重要作用，但也被认为是免疫反应的有力调节剂。我们旨在研究 1α,25(OH)2D(3)治疗对链脲佐菌素(STZ)诱导的大鼠胰岛素/ C 肽、过氧化氢酶、超氧化物歧化酶(SOD)和血糖的影响。
本研究共使用 40 只平均体重为 261.00+/-07.62 g 的雄性白化病大鼠。大鼠通过腹腔途径连续 5 天给予 40mg/kg 的 STZ 诱导糖尿病。部分糖尿病组和非糖尿病组接受 1α,25(OH)2D(3)治疗。在第 0、2、4 和 6 周时测量 SOD、胰岛素、C 肽、血糖、SOD 和过氧化氢酶水平。
与治疗前相比，所有组在第 6 周末的红细胞 SOD 水平均无显著差异。然而，与治疗前相比，非糖尿病对照组、非糖尿病维生素 D 组和糖尿病维生素 D 组的红细胞过氧化氢酶水平在第 6 周末均无显著差异，而糖尿病无维生素 D 组则有显著差异。未接受 1α,25(OH)2D(3)治疗的糖尿病无维生素 D 组胰岛素和 C 肽水平最高，胰岛素细胞浸润评分最高。
与其他组相比，接受治疗组的胰岛素和 C 肽水平较高，SOD、过氧化氢酶等氧化标志物水平较低，这可能是 1α,25(OH)2D(3)治疗阻止了细胞凋亡机制的介入。
